“For the second quarter of 2025, we expect total revenue to be in the range of $18.5 million to $19.0 million, reflecting continued strength for our patient affordability business, offset by weakness with our plasma business. We expect plasma revenues to be approximately 54% to 55% of revenue and patient affordability to be approximately 41% to 42% of revenue. Gross profit margins are expected to be 63.0% to 64.0%. Operating expenses are expected to be between $10.0 million and $11.0 million, of which depreciation and amortization will be approximately $2.0 million and stock-based compensation will be approximately $1.0 million. Adjusted EBITDA is expected to be in the range of $4.5 million to $5.0 million, or approximately 25.5% of revenue,” Baker concluded.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PAYS:
- PaySign Inc’s Earnings Call Highlights Growth Amid Challenges
- PaySign’s Strong Financial Performance and Growth Prospects Justify Buy Rating with Over 200% Potential Return
- PaySign’s Strong Financial Performance and Growth Prospects Justify Buy Rating
- Paysign price target lowered to $5 from $7 at Barrington
- Paysign, Inc. Reports Strong 2024 Financial Growth
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue